Chiesi is an Italy-based research company focusing on pharmaceutical solutions for respiratory therapeutics, specialist medicine, and rare diseases areas. It also has research and development centers in France, the US, and UK.
As part of the project, which seeks to identify compounds for further preclinical development, the contract research organization (CRO), Aptuit, will contribute its integrated early discovery capabilities, including medicinal chemistry and pharmacology in addition to drug metabolism and pharmacokinetics.
According to Dr. Jonathan Goldman, Aptuit CEO, the project expands on an existing relationship between the two companies in the field of respiratory drug discovery.
Dr. Mark Parry Billings, Corporate Drug Development Head, Chiesi Farmaceutici, added, “This alliance will allow our Project to progress effectively to the identification of lead compounds with a novel mechanism of action, leveraging our joint expertise in Respiratory drug discovery."